Page 249 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Summary, discussion and future perspectives
References
1. Zijlstra JM, Burggraaff CN, Kersten MJ, Barrington SF; EHA Scientific Working Group on Lymphoma. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? Haematologica. 2016 Nov;101(11):1279-1283.
2. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598‐1607.
3. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188‐1194.
4. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419‐2429.
5. André MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/ FIL H10 Trial. J Clin Oncol. 2017;35(16):1786-1794.
6. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790-2802.
7. Lymfoomwerkgroep HOVON. Richtlijn Hodgkin Lymfoom bij Volwassenen. Amsterdam: Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON); 2019. Available from: https:// hematologienederland.nl/wp-content/uploads/2020/01/Richtlijn-Hodgkin-lymfoom-HOVON- 2019-v-2019.11.13.pdf.
8. Dührsen U, Hüttmann A, Müller S, et al. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial). Blood. 2014;124(21):(Abstract 391).
9. Swinnen LJ, Li H, Quon A, et al. Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170(1):56-65.
10. Stewart DA, Kloiber R, Owen C, et al. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leuk Lymph. 2014;55(9):2064-2070.
11. Burggraaff CN, de Jong A, Hoekstra OS, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):65-79.
12. Burggraaff CN, Cornelisse AC, Hoekstra OS, et al. HOVON Imaging Working Group. Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J Nucl Med. 2018 Dec;59(12):1831-1836.
13. Burggraaff CN, Rahman F, Kaßner I, et al. PETRA Consortium. Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. Mol Imaging Biol. 2020 Aug;22(4):1102-1110.
14. Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. 2020 Oct 10;38(29):3377-3387.
15. Burggraaff CN, Eertink JJ, Lugtenburg PJ, et al. 18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study. J Nucl Med. 2022 Jul;63(7)1001- 1007.
16. Chamuleau MED, Burggraaff CN, Nijland M, et al. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2020 Dec 1;105(12):2805-2812.
17. Eertink JJ, Burggraaff CN, Heymans MW, et al. Optimal timing and criteria of interim-PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021 May;5(9):2375-2384.
247
9